Prosecution Insights
Last updated: November 20, 2026

Taeyoon Kim, USPTO Patent Examiner

Listed by the USPTO as KIM, TAEYOON

Tech Center 1600 • Art Units: 1631 1632 1641 1651

This examiner grants 51% of resolved cases

Analysis

Taeyoon Kim is a USPTO patent examiner in tech center 1600 and art unit 1631. Across 901 resolved cases, the allowance rate is 51.2%, the interview lift is 52.1%, and the median time to allowance is 1382 days. The profile indicates a demanding allowance environment in which interviews have a substantial recorded association with successful outcomes.

The listed companies are The Regents of the University of California, University of Louisville Research Foundation Inc., and Intellia Therapeutics Inc. Representative firms include ARRIGO, LEE, GUTTMAN & MOUTA-BELLUM LLP, FISH & RICHARDSON P.C. (TC), and ALSTON & BIRD LLP. Practitioners may benefit from early interview planning paired with carefully supported claim amendments.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

51.2%
Allow Rate
-8.8% vs TC avg
974
Total Applications
+52.1%
Interview Lift
1382
Avg Prosecution Days
Based on 901 resolved cases, 2023–2026

Rejection Statute Breakdown

5.2%
§101 Eligibility
13.7%
§102 Novelty
36.4%
§103 Obviousness
30.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18514880 CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS Final Rejection Regeneron Pharmaceuticals, Inc.
17611497 TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TLR-4 Final Rejection Merck Patent GmbH
18713196 ESTABLISHMENT OF ERYTHROID PRECURSOR CELL LINE CAPABLE OF CONDITIONAL MATURATION USING GENE OVEREXPRESSION Non-Final OA IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
18701379 METHOD FOR SUSPENSION CULTURE OF ADHERENT CELLS WITH STIRRING Non-Final OA NISSAN CHEMICAL CORPORATION
18737066 PROTOCOL GENERATING TISSUE SPECIFIC ENDOTHELIAL CELL LINE, NAMED LIOVECS (LUNG TISSUE IPSC ORIGIN VESSEL ORGANOID ENDOTHELIAL CELL) AND BIOVECS (BLOOD VESSEL STEM CELL IPSC ORIGIN VESSEL ORGANOID ENDOTHELIAL CELLS) Non-Final OA THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
18124656 HUMAN FACILITATING CELLS Final Rejection University of Louisville Research Foundation, Inc.
18002633 METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS Final Rejection THE CHILDREN'S MEDICAL CENTER CORPORATION
18300210 ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL Non-Final OA CREATIVE MEDICAL TECHNOLOGIES, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Taeyoon Kim's allowance rate?

51.2% of resolved applications examined by Taeyoon Kim were allowed (901 resolved cases), compared with 28.0% across Art Unit 1631 over the last five years.

Does an interview help with examiner Taeyoon Kim?

This examiner's interview lift is +52.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Taeyoon Kim take to allow a patent?

Applications allowed by Taeyoon Kim took 1,382 days on average from filing to allowance.

Which art unit does examiner Taeyoon Kim work in?

Taeyoon Kim examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month